Lyell Immunopharma, Inc. SEC filings LYEL
Lyell Immunopharma, Inc. has 359 filings in SEC EDGAR's recent list, going back to Mar 20, 2020. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 10, 2026 |
| DEF 14A | Proxy statement | Apr 21, 2025 | May 15, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2025 | May 15, 2025 |
| DEFA14A | Additional proxy material | Apr 22, 2024 | — |
| DEF 14A | Proxy statement | Apr 22, 2024 | Jun 14, 2023 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 8, 2022 |
Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LYEL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1806952
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.